In this edition of #CareTalk, CareCentrix CEO John Driscoll and I have a little fun at the expense of our neighbors to the North. Will Canada build a wall along its Southern border to keep out US patients?
(0:43) Are Canadians right to worry that Americans are going to clean out their pharmacies, leaving nothing for the locals?
(1:43) What are “authorized generics” and are they a good idea?
(3:22) Are skilled nursing facilities a piggybank for accountable care organizations?
We usually think of Canada as a divided nation, with the province of Quebec perennially at odds with the rest of the county and threatening to secede. I was in Montreal over the weekend and it’s fair to say there wasn’t much evidence of enthusiasm for the upcoming Canada Day (the rough equivalent of our 4th of July).
When it comes to stoking national pride, Canadians and Quebecers are united in their appreciation for universal health care and the Canadian passport. They also see eye-to-eye on the importance of the monarchy, Air Canada and Tim Hortons as national symbols, in that they don’t find them particularly important.
A national survey asked the question, “How important are each of the following as a source of personal or collective pride in Canada?”
Universal healthcare scored highest. Seventy three percent of Canadians and 70 percent of those from Quebec ranked it as very important. Anglophones and Francophones responded the same way.
We usually think of the United States of America, but when it comes to healthcare that is certainly not the case. If anything, Americans might be united against the idea of a Canadian-style system.
Kind of odd, then that the people living under that regime are so proud of it.
I was riding in an Uber the other night in Denver and got to talking with the driver. He said he’s from Kenya. I told him I never visited Kenya but was almost there about 10 years ago, but the conference I was attending got moved to Uganda due to post-election violence in his country.
When I explained that I had been there with the Forum for Collaborative HIV Research (now Forum for Collaborative Research) and Gates Foundation to talk about analyzing the demand for adult male circumcision to prevent HIV transmission, he told me he’d actually been circumcised under that program, which he called a very successful one.
Historically the Luo –of which he is a member– did not practice circumcision, but that changed as a result of a major public health campaign. Documentation of the campaign always stresses the voluntary nature of the program, because circumcision is sometimes coerced.
We arrived at our destination before I had the chance to tell the driver about checking into the hotel that Colonel Qadaffi had just checked out of.
Innovative Israeli technology companies have a huge impact around the world. Now, more of the country’s entrepreneurs are turning to connected health. mHealth Israel is at the center of this surge. Its upcoming mHealth Israel conference on September 14 will be the culmination of a nationwide week of activities.
I had planned to speak at the conference, but sadly won’t make it to Jerusalem this time around.
Levy shared his perspectives on mHealth in Israel and provided background on the upcoming mHealth conference.
(0:13) What’s the state of digital health in Israel? How does it differ from markets in the US and Europe?
(1:58) Israel is a small market and doesn’t trade much with its neighbors. Are most of these companies focused locally or are they looking at external markets?
(3:09) Describe the ecosystem. What is the typical interaction between the startup companies, hospitals and larger companies?
(7:10) What are some of the major themes you are seeing in health startups this year? Is it a change from the last couple years?
Medial EarlySign analyzes standard EHR data to identify individuals at high risk for disease. The company’s first solution, ColonFlag uses longitudinal blood test data to identify patients who are at high risk for colorectal cancer.
I spoke recently with Medial executive Tomer Amit, who filled me in on the company’s approach and explained why the company has been named a Cool Vendor in AI by Gartner.
(0:15) What unmet need are you serving?
(1:05) You talk about using data that’s already available. What kind of data?
(3:02) When you mention “historical data” are you talking about longitudinal data for an individual patient or aggregated data for a population?
(4:18) Why is colorectal cancer an initial focus for the company, with your ColonFlag solution?
(5:13) Does ColonFlag replace colonoscopy or encourage someone to get one if they have an indicator that they are at greater risk?
(6:38) I see how it could help an individual. Would it actually help at the population level?
(7:45) You started in Israel and the EU, which have strong longitudinal medical records. Can the approach be applied in the US where that’s not the case?
(10:41) You have run your tests in different places around the world. Does the model differ by population or is there a universal algorithm?
(12:10) How do you protect your intellectual property? Once you are out there, are there just rules of thumb people can use instead of working with you?
(13:14) What traction have you gained with customers or partners? What industry recognition have you received?
(14:45) Are there other domains you are investigating beyond colon cancer? Other data beyond blood tests?
(15:58) What’s your 5-10 year vision of what’s possible and what Medial’s role will be?